<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01944046</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00063950</org_study_id>
    <secondary_id>1U01HD073984</secondary_id>
    <secondary_id>13-0593</secondary_id>
    <nct_id>NCT01944046</nct_id>
  </id_info>
  <brief_title>Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors</brief_title>
  <acronym>SOARS-B</acronym>
  <official_title>Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linmarie Sikich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn about the effects of supplemental intranasal&#xD;
      oxytocin as a treatment for improving social difficulties in children and adolescents with&#xD;
      autism. This study will also provide additional information about the safety and tolerability&#xD;
      of intranasal oxytocin. Investigators expect oxytocin will increase social motivation,&#xD;
      improving daily living skills and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a tremendous unmet need for accessible treatments that address core symptoms of ASD&#xD;
      and are safe for sustained use. The Study of Oxytocin in ASD to improve Reciprocal Social&#xD;
      Behaviors or (SOARS-B) will test a very promising potential treatment-intranasal oxytocin-for&#xD;
      ASD's fundamental social communication deficits in a large, group of verbal and nonverbal&#xD;
      children. SOARS-B will also provide information about the regulation of DNA methylation and&#xD;
      transcription of the oxytocin receptor gene (OXTR), as well as other genes relevant to&#xD;
      oxytocin's CNS activity, as a function of time and in response to oxytocin treatment. These&#xD;
      data will fill a key gap in our understanding of oxytocin's role in ASD and its ability to&#xD;
      alter epigenetic modifications of the OXTR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2014</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-blind, placebo-controlled clinical trial for 24 weeks. Followed by 24 week open label treatment period in which ALL participants receive Oxytocin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity</measure>
    <time_frame>Least Mean Squares Double-blind phase: change from baseline to week 24</time_frame>
    <description>The primary outcome is Change in Aberrant Behavior Checklist-Modified Social Withdrawal subscale- a measure of reciprocal social behaviors. ABC-mSW is a modification of the ABC-Lethargy subscale. The ABC-mSW consists of the sum of questions 5,12,16, 20, 23, 26, 30, 37, 40, 42, 43, 55, and 58. In contrast to the ABC-Lethargy subscale it eliminates question 3 (listless, sluggish, inactive), question 32 (sits or stands in one position for a long time), and question 53 (inactive, never moves spontaneously). Thirteen individual items are scored 0-3, therefore the range is 0-39. Higher score indicates lower social reciprocity. Repeated measures were obtained at baseline, weeks 4, 8, 12, 16, 20, 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity</measure>
    <time_frame>Least mean squares for Open Label: Change between weeks 24-48</time_frame>
    <description>The ABC-mSW is described above and involves 13 items reflecting lack of reciprocal interaction. Each item is scored from 0 (never shows behavior) to 3 (behavior is a major problem). The range is 0-39. Higher scores indicate worse reciprocal social functioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sociability Factor (SF)</measure>
    <time_frame>Double-blind phase: change in least means squares between week 0 &amp; 24.</time_frame>
    <description>The Sociability Factor (SF) is a summed measure of the13 items of the ABC-SW and the 18 items of the Pervasive Development Disorders Behavior Inventory-Screening Version (PDDBI-SV).The PDDBI-SV assesses both adaptive social behaviors and social problems typical of ASD. The adaptive behaviors are reverse scored so that all the analyzed scores range from 0-performing in a neurotypical fashion to 3 typically performs in a way associated with ASD. the total # of items on this summed measure is 31 with a range from 0 to 93. More impaired social functioning indicated by higher scores. This measure was changed to a secondary outcome in the final statistical analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Social Responsiveness Scale-2 (SRS-2) Social Motivation Subscale Score</measure>
    <time_frame>Double-blind phase: baseline, weeks 12, 24</time_frame>
    <description>The SRS-Social Motivation subscale was developed to provide a quantitative measure of social impairments typically observed in ASD in children 3-18 years. Reported as T-score with a range of 38-90 for both boys and girls. Higher score indicates more severe clinical condition. Lower value in change indicates more improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stanford Binet-5th Edition (SB-5) IQ Score</measure>
    <time_frame>Double-blind phase: baseline to week 24</time_frame>
    <description>Cognitive skills will be assessed using the Stanford Binet-5th Edition (SB-5) (Roid). Acceptable IQ range is 47-153, with higher score being better. Higher change scores indicate more improvement.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Social Responsiveness Scale-2 (SRS-2) Social Motivation Subscale Score</measure>
    <time_frame>Open Label: weeks 24, 48</time_frame>
    <description>The SRS-Social Motivation subscale was developed to provide a quantitative measure of social impairments typically observed in ASD in children 3-18 years. Reported as T-score with a range of 38-90 for both boys and girls. Higher score indicates more severe clinical condition. Lower value in change indicates more improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Vineland II Adaptive Behavior Scales (VABS-II) Daily Living Domain Score</measure>
    <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
    <description>Functional skills will be assessed using the VABS-II Daily Living Domain Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Caregiver Strain Questionnaire (CSQ) Subjective Internalizing Subscale Mean Score</measure>
    <time_frame>Open Label: weeks 24, 48</time_frame>
    <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. Each item on the subjective internalizing CSQ subscale is rated from 1 to 5. Then all items within the subscale are summed and the mean is determined based on the number of items in the subscale. Higher score indicates more caregiver strain. Lower value in change indicates more improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Vineland II Adaptive Behavior Scales (VABS-II) Communication Domain Score</measure>
    <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
    <description>Functional skills will be assessed using the VABS-II Communication Domain Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Caregiver Strain Questionnaire (CSQ) Subjective Internalizing Subscale Score</measure>
    <time_frame>Double-blind phase: baseline, week 24</time_frame>
    <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. CSQ subscale scores are ranged from 1 to 5. with each item of the subscale having the same range, the sum of the items within the subscale are summed, and the mean score is determined (I.e. a single # between 1 and 5) and reported. Higher scores indicate more caregiver strain. Lower value in change indicates more improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Vineland II Adaptive Behavior Scales (VABS-II) Socialization Domain Score</measure>
    <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
    <description>Functional skills will be assessed using the VABS-II Socialization Domain Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Caregiver Strain Questionnaire (CSQ) Objective Subscale Score</measure>
    <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
    <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. CSQ subscale scores are ranged from 1 to 5. Higher score indicates more caregiver strain. Lower value in change indicates more improvement. The analysis directions for the instrument that are used in these analyses are the mean of all the responses in the scale or subscale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Caregiver Strain Questionnaire (CSQ) Subjective Externalizing Subscale Score</measure>
    <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
    <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. CSQ subscale scores are ranged from 1 to 5. Higher score indicates more caregiver strain. Lower value in change indicates more improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Vineland II Adaptive Behavior Scales (VABS-II) Composite Score</measure>
    <time_frame>Double-blind phase: baseline, week 24</time_frame>
    <description>Functional skills including communication will be assessed using the VABS-II Adaptive Behavior Composite Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Clinical Global Impressions -Improvement Score (CGI-I)</measure>
    <time_frame>Double blind phase: change from Baseline to week 12, and week 24. Open label phase change from week 24 to week 48</time_frame>
    <description>The Clinical Global Impressions - Improvement score and Severity score, which is routinely used in pharmacologic clinical trials, will capture the study physician's global impression of response. scores of 1 and 2 are considered as a percentage of total subjects in arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Reading Mind in the Eyes Test is an Objective Measures of the Extent to Which Verbal Participants With Rudimentary Knowledge of Emotion Names Are Able to Correctly Identify the Emotion Shown in a Black and White Picture of the Eyes and Nose of an Actor.</measure>
    <time_frame>Double blind phase: change from Baseline and week 24. Note: only those who demonstrated understanding of these concepts were included in sample.</time_frame>
    <description>This computerized task consists of a series of pictures of eyes in which the participant needs to determine which emotion the eyes are expressing from 4 emotions listed along with the picture. The outcome is the % of pictures with correct emotion identified. The range is 0 to 100%. The larger percent identified correctly indicates better ability to perceive emotions. An increase or positive change indicates better ability to identify emotions since baseline.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>DB Placebo Nasal Spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment during weeks 0-24 double blind phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DB Oxytocin Nasal Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DB Oxytocin- quadruply masked treatment with intranasal oxytocin during weeks 0-24 of study during double blind phase of study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>open label intranasal oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non masked treatment with intranasal oxytocin from weeks 24-48 in those participants who completed first 24 weeks of double blind treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double blind phase Placebo Nasal Spray</intervention_name>
    <description>This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
    <arm_group_label>DB Placebo Nasal Spray</arm_group_label>
    <other_name>DB Placebo (PL)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>double Blind Oxytocin Nasal Spray</intervention_name>
    <description>Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
    <arm_group_label>DB Oxytocin Nasal Spray</arm_group_label>
    <other_name>DB Intranasal Oxytocin (OT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Open Label intranasal oxytocin</intervention_name>
    <description>All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin</description>
    <arm_group_label>open label intranasal oxytocin</arm_group_label>
    <other_name>open label treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be between the ages of 3 years 0 months and 17 years 11 months at the time of&#xD;
             randomization&#xD;
&#xD;
          -  Be diagnosed by clinician experienced in assessment of ASD with autistic disorder,&#xD;
             Asperger's syndrome, or PDD-NOS using DSM-V-TR criteria&#xD;
&#xD;
          -  Must have clinical diagnosis of ASD confirmed using the Autism Diagnostic Observation&#xD;
             Scale (ADOS, Lord et al., 2001)&#xD;
&#xD;
          -  Must have clinical diagnosis of ASD confirmed using the Autism Diagnostic&#xD;
             Interview-Revised (ADI-R, Rutter, 2003). ASD criteria proposed by Risi (2006).&#xD;
             Specifically, subject must be within 1 point of autism criteria on both social and&#xD;
             communication domains of the ADI or meet autism criteria in one of these ADI domains&#xD;
             and come within 2 points of autism criteria in the other&#xD;
&#xD;
          -  Have a guardian who is able to provide informed consent&#xD;
&#xD;
          -  If cognitively able, subject must be able to provide informed assent/consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a known diagnosis of Rett Syndrome or Childhood Disintegrative Disorder, or have&#xD;
             marked sensory impairment such as deafness or blindness&#xD;
&#xD;
          -  Have active cardiovascular disease or renal disease that is not controlled by&#xD;
             medication&#xD;
&#xD;
          -  Subjects who are pregnant, lactating, or who refuse to practice contraception if&#xD;
             sexually active&#xD;
&#xD;
          -  Subjects who have had changes in allied health therapies, behavioral or educational&#xD;
             interventions within the two months prior to randomization other than those associated&#xD;
             with school holidays&#xD;
&#xD;
          -  Subjects who have had changes in psychiatric medications within 4 weeks of&#xD;
             randomization&#xD;
&#xD;
          -  Subjects who have had previous chronic treatment with oxytocin&#xD;
&#xD;
          -  Subjects who have caretakers who are unable to speak English, be consistently present&#xD;
             at visits to report on symptoms, or are otherwise judged as unable to comply with the&#xD;
             protocol by the data collection site team&#xD;
&#xD;
          -  Subjects with active seizures within the 6 months preceding screening or baseline&#xD;
             -added part way through study in response to subject death.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linmarie Sikich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurie Center for Autism, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Autism and the Developing Brain</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Center for Autism and Brain Development</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University , Genetics Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Spanos M, Chandrasekhar T, Kim SJ, Hamer RM, King BH, McDougle CJ, Sanders KB, Gregory SG, Kolevzon A, Veenstra-VanderWeele J, Sikich L. Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B). Contemp Clin Trials. 2020 Nov;98:106103. doi: 10.1016/j.cct.2020.106103. Epub 2020 Aug 8.</citation>
    <PMID>32777383</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 13, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <results_first_submitted>July 31, 2020</results_first_submitted>
  <results_first_submitted_qc>December 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <disposition_first_submitted>November 29, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>November 29, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 21, 2018</disposition_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Linmarie Sikich</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>autism, ASD, autistic, Asperger's, PDD-NOS, oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Most data will be available on NDAR, but will not be identifiable.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01944046/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin Nasal Spray</title>
          <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized to DB</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Worsening</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not have baseline ABC-SW</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not have a postbaseline ABC SW</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Eligible and Consented</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Worsening</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Double-Blind Full Analysis Set (FAS). The DB FAS was defined as having both baseline and at least one post-baseline ABC-SW assessment. The DB-FAS excludes 7 participants randomized to oxytocin (2 with no baseline ABC-SW and 5 with no post-baseline ABC-SW) and 6 participants assigned to placebo who had no post-baseline ABC-SW.</population>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin Nasal Spray</title>
          <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="139"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="277"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" spread="4.06"/>
                    <measurement group_id="B2" value="10.4" spread="3.99"/>
                    <measurement group_id="B3" value="10.4" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aberrant Behavior Checklist Social Withdrawal Subscale Score (ABC-SW) abc-SW (mean</title>
          <description>the Aberrant Behavior Scale Social withdrawal score assesses reciprocal social behaviors. It is composed of 13 questions from the Aberrant Behavior Scale Lethargy subscale that consists of 16 questions. The ABC-SW does not include the 3 questions (i.e. 3,32,53) of the Lethargy subscale that refer to sedentary behaviors. Score for each item ranges from 0 (not at all a problem) to 3 (a serious problem). Items are summed to give a minimal score of 0 and a maximal score of 39. Lower Scores are better</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.0" spread="6.9"/>
                    <measurement group_id="B2" value="11.6" spread="7.8"/>
                    <measurement group_id="B3" value="11.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity</title>
        <description>The primary outcome is Change in Aberrant Behavior Checklist-Modified Social Withdrawal subscale- a measure of reciprocal social behaviors. ABC-mSW is a modification of the ABC-Lethargy subscale. The ABC-mSW consists of the sum of questions 5,12,16, 20, 23, 26, 30, 37, 40, 42, 43, 55, and 58. In contrast to the ABC-Lethargy subscale it eliminates question 3 (listless, sluggish, inactive), question 32 (sits or stands in one position for a long time), and question 53 (inactive, never moves spontaneously). Thirteen individual items are scored 0-3, therefore the range is 0-39. Higher score indicates lower social reciprocity. Repeated measures were obtained at baseline, weeks 4, 8, 12, 16, 20, 24.</description>
        <time_frame>Least Mean Squares Double-blind phase: change from baseline to week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity</title>
          <description>The primary outcome is Change in Aberrant Behavior Checklist-Modified Social Withdrawal subscale- a measure of reciprocal social behaviors. ABC-mSW is a modification of the ABC-Lethargy subscale. The ABC-mSW consists of the sum of questions 5,12,16, 20, 23, 26, 30, 37, 40, 42, 43, 55, and 58. In contrast to the ABC-Lethargy subscale it eliminates question 3 (listless, sluggish, inactive), question 32 (sits or stands in one position for a long time), and question 53 (inactive, never moves spontaneously). Thirteen individual items are scored 0-3, therefore the range is 0-39. Higher score indicates lower social reciprocity. Repeated measures were obtained at baseline, weeks 4, 8, 12, 16, 20, 24.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double-blind baseline to w4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.81" spread="0.39"/>
                    <measurement group_id="O2" value="8.68" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-blind baseline to w8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" spread="0.45"/>
                    <measurement group_id="O2" value="8.68" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-blind baseline-w12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48" spread="0.43"/>
                    <measurement group_id="O2" value="8.13" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w0- w16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.99" spread="0.46"/>
                    <measurement group_id="O2" value="8.04" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w0- w20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.81" spread="0.05"/>
                    <measurement group_id="O2" value="7.75" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w0-w24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" spread="0.46"/>
                    <measurement group_id="O2" value="8.05" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.503</p_value>
            <p_value_desc>not adjusted primary outcome</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>adjusted for baseline, age category, functionality category</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity</title>
        <description>The ABC-mSW is described above and involves 13 items reflecting lack of reciprocal interaction. Each item is scored from 0 (never shows behavior) to 3 (behavior is a major problem). The range is 0-39. Higher scores indicate worse reciprocal social functioning.</description>
        <time_frame>Least mean squares for Open Label: Change between weeks 24-48</time_frame>
        <population>Open Label phase participants in OLE FAS excluding 2 participants without usable ABC-sws (either w24 or at least one pw24 ABC-sw.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity</title>
          <description>The ABC-mSW is described above and involves 13 items reflecting lack of reciprocal interaction. Each item is scored from 0 (never shows behavior) to 3 (behavior is a major problem). The range is 0-39. Higher scores indicate worse reciprocal social functioning.</description>
          <population>Open Label phase participants in OLE FAS excluding 2 participants without usable ABC-sws (either w24 or at least one pw24 ABC-sw.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Open Label week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.83" lower_limit="7.11" upper_limit="8.55"/>
                    <measurement group_id="O2" value="7.81" lower_limit="7.09" upper_limit="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open Label week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.99" lower_limit="6.10" upper_limit="7.89"/>
                    <measurement group_id="O2" value="6.78" lower_limit="5.89" upper_limit="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.61</p_value>
            <p_value_desc>not adjusted primary outcome, p threshold 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>adjustment for value at week 24,</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sociability Factor (SF)</title>
        <description>The Sociability Factor (SF) is a summed measure of the13 items of the ABC-SW and the 18 items of the Pervasive Development Disorders Behavior Inventory-Screening Version (PDDBI-SV).The PDDBI-SV assesses both adaptive social behaviors and social problems typical of ASD. The adaptive behaviors are reverse scored so that all the analyzed scores range from 0-performing in a neurotypical fashion to 3 typically performs in a way associated with ASD. the total # of items on this summed measure is 31 with a range from 0 to 93. More impaired social functioning indicated by higher scores. This measure was changed to a secondary outcome in the final statistical analysis plan.</description>
        <time_frame>Double-blind phase: change in least means squares between week 0 &amp; 24.</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sociability Factor (SF)</title>
          <description>The Sociability Factor (SF) is a summed measure of the13 items of the ABC-SW and the 18 items of the Pervasive Development Disorders Behavior Inventory-Screening Version (PDDBI-SV).The PDDBI-SV assesses both adaptive social behaviors and social problems typical of ASD. The adaptive behaviors are reverse scored so that all the analyzed scores range from 0-performing in a neurotypical fashion to 3 typically performs in a way associated with ASD. the total # of items on this summed measure is 31 with a range from 0 to 93. More impaired social functioning indicated by higher scores. This measure was changed to a secondary outcome in the final statistical analysis plan.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DB w0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="1.24"/>
                    <measurement group_id="O2" value="36.1" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w0-w4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.57" spread="0.69"/>
                    <measurement group_id="O2" value="-5.81" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w0-w8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.99" spread="0.66"/>
                    <measurement group_id="O2" value="-6.30" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w0-w12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.40" spread="0.66"/>
                    <measurement group_id="O2" value="-6.79" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w0-w16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.82" spread="0.70"/>
                    <measurement group_id="O2" value="-7.28" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w0-w20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.24" spread="0.88"/>
                    <measurement group_id="O2" value="-7.77" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w0-w24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.66" spread="0.78"/>
                    <measurement group_id="O2" value="-8.27" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Social Responsiveness Scale-2 (SRS-2) Social Motivation Subscale Score</title>
        <description>The SRS-Social Motivation subscale was developed to provide a quantitative measure of social impairments typically observed in ASD in children 3-18 years. Reported as T-score with a range of 38-90 for both boys and girls. Higher score indicates more severe clinical condition. Lower value in change indicates more improvement.</description>
        <time_frame>Double-blind phase: baseline, weeks 12, 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Social Responsiveness Scale-2 (SRS-2) Social Motivation Subscale Score</title>
          <description>The SRS-Social Motivation subscale was developed to provide a quantitative measure of social impairments typically observed in ASD in children 3-18 years. Reported as T-score with a range of 38-90 for both boys and girls. Higher score indicates more severe clinical condition. Lower value in change indicates more improvement.</description>
          <population>Full Analysis Set</population>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double-blind baseline to week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.58" spread="0.68"/>
                    <measurement group_id="O2" value="-5.72" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-blind baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.49" spread="0.70"/>
                    <measurement group_id="O2" value="-5.42" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stanford Binet-5th Edition (SB-5) IQ Score</title>
        <description>Cognitive skills will be assessed using the Stanford Binet-5th Edition (SB-5) (Roid). Acceptable IQ range is 47-153, with higher score being better. Higher change scores indicate more improvement.</description>
        <time_frame>Double-blind phase: baseline to week 24</time_frame>
        <population>Participants with scores collected at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stanford Binet-5th Edition (SB-5) IQ Score</title>
          <description>Cognitive skills will be assessed using the Stanford Binet-5th Edition (SB-5) (Roid). Acceptable IQ range is 47-153, with higher score being better. Higher change scores indicate more improvement.</description>
          <population>Participants with scores collected at baseline and week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="11.64"/>
                    <measurement group_id="O2" value="1.0" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Social Responsiveness Scale-2 (SRS-2) Social Motivation Subscale Score</title>
        <description>The SRS-Social Motivation subscale was developed to provide a quantitative measure of social impairments typically observed in ASD in children 3-18 years. Reported as T-score with a range of 38-90 for both boys and girls. Higher score indicates more severe clinical condition. Lower value in change indicates more improvement.</description>
        <time_frame>Open Label: weeks 24, 48</time_frame>
        <population>Open Label phase participants</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Social Responsiveness Scale-2 (SRS-2) Social Motivation Subscale Score</title>
          <description>The SRS-Social Motivation subscale was developed to provide a quantitative measure of social impairments typically observed in ASD in children 3-18 years. Reported as T-score with a range of 38-90 for both boys and girls. Higher score indicates more severe clinical condition. Lower value in change indicates more improvement.</description>
          <population>Open Label phase participants</population>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Open Label week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" spread="1.37"/>
                    <measurement group_id="O2" value="86.6" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open Label week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9" spread="1.83"/>
                    <measurement group_id="O2" value="83.0" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Vineland II Adaptive Behavior Scales (VABS-II) Daily Living Domain Score</title>
        <description>Functional skills will be assessed using the VABS-II Daily Living Domain Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
        <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vineland II Adaptive Behavior Scales (VABS-II) Daily Living Domain Score</title>
          <description>Functional skills will be assessed using the VABS-II Daily Living Domain Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double-blind baseline to week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="1.10"/>
                    <measurement group_id="O2" value="1.24" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open Label week 24 to week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.19"/>
                    <measurement group_id="O2" value="0.62" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Caregiver Strain Questionnaire (CSQ) Subjective Internalizing Subscale Mean Score</title>
        <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. Each item on the subjective internalizing CSQ subscale is rated from 1 to 5. Then all items within the subscale are summed and the mean is determined based on the number of items in the subscale. Higher score indicates more caregiver strain. Lower value in change indicates more improvement.</description>
        <time_frame>Open Label: weeks 24, 48</time_frame>
        <population>Full Analysis Set participants who entered double blind and have values at week 24 AND 48</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Caregiver Strain Questionnaire (CSQ) Subjective Internalizing Subscale Mean Score</title>
          <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. Each item on the subjective internalizing CSQ subscale is rated from 1 to 5. Then all items within the subscale are summed and the mean is determined based on the number of items in the subscale. Higher score indicates more caregiver strain. Lower value in change indicates more improvement.</description>
          <population>Full Analysis Set participants who entered double blind and have values at week 24 AND 48</population>
          <units>mean score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Open Label week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="0.99"/>
                    <measurement group_id="O2" value="2.85" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open Label week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="0.99"/>
                    <measurement group_id="O2" value="2.85" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Vineland II Adaptive Behavior Scales (VABS-II) Communication Domain Score</title>
        <description>Functional skills will be assessed using the VABS-II Communication Domain Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
        <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vineland II Adaptive Behavior Scales (VABS-II) Communication Domain Score</title>
          <description>Functional skills will be assessed using the VABS-II Communication Domain Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double-blind baseline to week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="0.89"/>
                    <measurement group_id="O2" value="2.27" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open Label week 24 to week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="1.35"/>
                    <measurement group_id="O2" value="5.98" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Caregiver Strain Questionnaire (CSQ) Subjective Internalizing Subscale Score</title>
        <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. CSQ subscale scores are ranged from 1 to 5. with each item of the subscale having the same range, the sum of the items within the subscale are summed, and the mean score is determined (I.e. a single # between 1 and 5) and reported. Higher scores indicate more caregiver strain. Lower value in change indicates more improvement.</description>
        <time_frame>Double-blind phase: baseline, week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Caregiver Strain Questionnaire (CSQ) Subjective Internalizing Subscale Score</title>
          <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. CSQ subscale scores are ranged from 1 to 5. with each item of the subscale having the same range, the sum of the items within the subscale are summed, and the mean score is determined (I.e. a single # between 1 and 5) and reported. Higher scores indicate more caregiver strain. Lower value in change indicates more improvement.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.07"/>
                    <measurement group_id="O2" value="-0.29" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Vineland II Adaptive Behavior Scales (VABS-II) Socialization Domain Score</title>
        <description>Functional skills will be assessed using the VABS-II Socialization Domain Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
        <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vineland II Adaptive Behavior Scales (VABS-II) Socialization Domain Score</title>
          <description>Functional skills will be assessed using the VABS-II Socialization Domain Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double-blind baseline to week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.45" spread="1.27"/>
                    <measurement group_id="O2" value="4.87" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open Label week 24 to week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="1.11"/>
                    <measurement group_id="O2" value="0.54" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Caregiver Strain Questionnaire (CSQ) Objective Subscale Score</title>
        <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. CSQ subscale scores are ranged from 1 to 5. Higher score indicates more caregiver strain. Lower value in change indicates more improvement. The analysis directions for the instrument that are used in these analyses are the mean of all the responses in the scale or subscale.</description>
        <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Caregiver Strain Questionnaire (CSQ) Objective Subscale Score</title>
          <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. CSQ subscale scores are ranged from 1 to 5. Higher score indicates more caregiver strain. Lower value in change indicates more improvement. The analysis directions for the instrument that are used in these analyses are the mean of all the responses in the scale or subscale.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double-blind baseline to week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.06"/>
                    <measurement group_id="O2" value="-0.22" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open Label week 24 to week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.06"/>
                    <measurement group_id="O2" value="0.44" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Caregiver Strain Questionnaire (CSQ) Subjective Externalizing Subscale Score</title>
        <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. CSQ subscale scores are ranged from 1 to 5. Higher score indicates more caregiver strain. Lower value in change indicates more improvement.</description>
        <time_frame>Double-blind phase: baseline, week 24; Open Label: week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Caregiver Strain Questionnaire (CSQ) Subjective Externalizing Subscale Score</title>
          <description>Caregiver questionnaire that assesses the impact of caring for the proband on caregiver and family. CSQ subscale scores are ranged from 1 to 5. Higher score indicates more caregiver strain. Lower value in change indicates more improvement.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double-blind baseline to week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.04"/>
                    <measurement group_id="O2" value="-0.04" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open Label week 24 to week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.07"/>
                    <measurement group_id="O2" value="0" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Vineland II Adaptive Behavior Scales (VABS-II) Composite Score</title>
        <description>Functional skills including communication will be assessed using the VABS-II Adaptive Behavior Composite Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
        <time_frame>Double-blind phase: baseline, week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vineland II Adaptive Behavior Scales (VABS-II) Composite Score</title>
          <description>Functional skills including communication will be assessed using the VABS-II Adaptive Behavior Composite Score. Uses standard score with a mean of 100 and SD of 15 with a range of 20-160. Higher score is better. Higher value in change indicates more improvement.</description>
          <population>Full Analysis Set</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="1.26"/>
                    <measurement group_id="O2" value="1.50" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Clinical Global Impressions -Improvement Score (CGI-I)</title>
        <description>The Clinical Global Impressions - Improvement score and Severity score, which is routinely used in pharmacologic clinical trials, will capture the study physician's global impression of response. scores of 1 and 2 are considered as a percentage of total subjects in arm</description>
        <time_frame>Double blind phase: change from Baseline to week 12, and week 24. Open label phase change from week 24 to week 48</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Global Impressions -Improvement Score (CGI-I)</title>
          <description>The Clinical Global Impressions - Improvement score and Severity score, which is routinely used in pharmacologic clinical trials, will capture the study physician's global impression of response. scores of 1 and 2 are considered as a percentage of total subjects in arm</description>
          <population>full analysis set</population>
          <units>percentage of participants in arm</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reading Mind in the Eyes Test is an Objective Measures of the Extent to Which Verbal Participants With Rudimentary Knowledge of Emotion Names Are Able to Correctly Identify the Emotion Shown in a Black and White Picture of the Eyes and Nose of an Actor.</title>
        <description>This computerized task consists of a series of pictures of eyes in which the participant needs to determine which emotion the eyes are expressing from 4 emotions listed along with the picture. The outcome is the % of pictures with correct emotion identified. The range is 0 to 100%. The larger percent identified correctly indicates better ability to perceive emotions. An increase or positive change indicates better ability to identify emotions since baseline.</description>
        <time_frame>Double blind phase: change from Baseline and week 24. Note: only those who demonstrated understanding of these concepts were included in sample.</time_frame>
        <population>only subjects who could define feelings from fluently verbal subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Reading Mind in the Eyes Test is an Objective Measures of the Extent to Which Verbal Participants With Rudimentary Knowledge of Emotion Names Are Able to Correctly Identify the Emotion Shown in a Black and White Picture of the Eyes and Nose of an Actor.</title>
          <description>This computerized task consists of a series of pictures of eyes in which the participant needs to determine which emotion the eyes are expressing from 4 emotions listed along with the picture. The outcome is the % of pictures with correct emotion identified. The range is 0 to 100%. The larger percent identified correctly indicates better ability to perceive emotions. An increase or positive change indicates better ability to identify emotions since baseline.</description>
          <population>only subjects who could define feelings from fluently verbal subgroup</population>
          <units>percentage of correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DB w0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" spread="18.76"/>
                    <measurement group_id="O2" value="48.2" spread="18.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB w24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" spread="14.02"/>
                    <measurement group_id="O2" value="49.92" spread="13.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through post-treatment follow-up, approximately 55 weeks.</time_frame>
      <desc>Adverse events collected on Safety Population (subjects who started each phase).</desc>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin Nasal Spray: Double-blind Phase</title>
          <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Nasal Spray: Double-blind Phase</title>
          <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
        </group>
        <group group_id="E3">
          <title>Oxytocin Nasal Spray: Open Label Phase</title>
          <description>Oxytocin&#xD;
Oxytocin Nasal Spray: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Nasal Spray: Open Label Phase</title>
          <description>Placebo&#xD;
Placebo Nasal Spray: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will be no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Tendency To Bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cardiac Rhythm Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Ache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Ear Congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Precocious Puberty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Eye Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Or Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Vomiting Or Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Tooth Disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Encopresis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Salivary Hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Anorectal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Energy Increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Chest Pain Or Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Enamel Discoloration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Intentional Self-Injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pituitary Analyses Anterior</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Abnormal Urinalysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Abnormal Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Abnormal Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Growing Pains</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Specific Muscle Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Skeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Initial Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Stereotypy</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Terminal Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Middle Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Speech Disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Ganglion Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Seizure Or Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Coordination Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sleep Walking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Negativism</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Aggression Or Hostility</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Anger Or Irritability</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Frustration</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Inappropriate Affect</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Psychomotor Hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Impulse-Control Disorder</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Disturbance In Attention</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Mood Swings</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Obsessive Rumination</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Apathy Or Boredom</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Perseveration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Mania Or Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pressure Of Speech</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Micturition Frequency Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Libido Increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Menstrual Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Nasal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Rhinitis Nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Wart</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linmarie Sikich, M.D.</name_or_title>
      <organization>Duke University</organization>
      <phone>919-681-0026</phone>
      <email>linmarie.sikich@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

